glp 1 drugs and addiction GLP-1 may help curb by targeting reward pathways GLP‑1 Drugs May Be the
Description
Ramnanan CJ, Edgerton DS, Kraft G, et al
These data align with an integrated analysis of 36 clinical studies that affirmed cardiovascular safety with up to 4-years treatment with either DPP-4 inhibitors or GLP-1R agonists [655]
A large proportion of patients progress to AD, while some MCI patients may remain stable (58)
These remain the first-line pharmacological treatments supported by robust clinical trial evidence and cost-effectiveness analyses
The Lancet, 397 ,
10.1177/20420188221112490 86 WeiY.MojsovS
